• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Development of a Guideline on Clinical investigation of Medicinal Product in the Treatment of Depression in Japan].

作者信息

Nakabayashi Tetsuo

机构信息

National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8551, Japan.

出版信息

Nihon Shinkei Seishin Yakurigaku Zasshi. 2011 Aug;31(4):169-76.

PMID:21941851
Abstract

Drug development is one of the methods for qualitative improvement of medical treatment. The Ministry of Health, Labour and Welfare in Japan (MHLW) published "A Guideline on Clinical Investigation of Medicinal Product in the Treatment of Depression" in November 2010. The guideline was developed by a Japanese expert working group in psychiatry and regulatory science. The purpose of the guideline is to describe accepted principles and practices in the conduct of both individual clinical trials and development strategy for new medicinal products intended to be used for treating depression and to facilitate efficient drug development. This document describes the major issues discussed during the guideline development. This work was supported by Grants-in-Aid from the Research Committee of "A Guideline on Clinical Investigation of Medicinal Product in the Treatment of Depression", MHLW.

摘要

相似文献

1
[Development of a Guideline on Clinical investigation of Medicinal Product in the Treatment of Depression in Japan].
Nihon Shinkei Seishin Yakurigaku Zasshi. 2011 Aug;31(4):169-76.
2
[Current and future views from pharmaceutical industry perspectives on development of antidepressants].[制药行业对抗抑郁药研发的当前及未来观点]
Nihon Shinkei Seishin Yakurigaku Zasshi. 2011 Aug;31(4):181-6.
3
[Expectation for future development of antidepressant based on the newly published guideline focusing on clinical evaluation of antidepressants].基于聚焦抗抑郁药临床评估的新发布指南对抗抑郁药未来发展的期望
Nihon Shinkei Seishin Yakurigaku Zasshi. 2011 Aug;31(4):177-80.
4
[The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].[日本抗癌药物临床评价方法指南的修订]
Gan To Kagaku Ryoho. 2006 Jul;33(7):1015-9.
5
[The Multidisciplinary Guideline for Depression: a commentary].[《抑郁症多学科指南:一篇评论》]
Tijdschr Psychiatr. 2006;48(12):921-5.
6
[Present condition of and future perspective for antipsychotic agents--guidelines on clinical investigation of medical products in the treatment of depression].[抗精神病药物的现状与未来展望——药品治疗抑郁症临床研究指南]
Nihon Shinkei Seishin Yakurigaku Zasshi. 2011 Aug;31(4):167.
7
Consensus guidelines in the treatment of major depressive disorder.重度抑郁症治疗的共识指南。
J Clin Psychiatry. 1998;59 Suppl 20:73-84.
8
Exploratory clinical trials: implementation modes & guidelines, scope and regulatory framework.探索性临床试验:实施模式与指南、范围及监管框架。
Therapie. 2009 May-Jun;64(3):149-59. doi: 10.2515/therapie/2009022. Epub 2009 Aug 13.
9
Factors contributing to failed trials of new agents: can technology prevent some problems?
J Clin Psychiatry. 2002;63 Suppl 2:8-13.
10
Study designs and outcomes in antidepressant clinical trials.抗抑郁药物临床试验的研究设计与结果
Essent Psychopharmacol. 2005;6(4):221-6.